E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
Bajrami, Ilirjana; Marlow, Rebecca; van de Ven, Marieke; Brough, Rachel; Pemberton, Helen N; Frankum, Jessica; Song, Feifei; Rafiq, Rumana; Konde, Asha; Krastev, Dragomir B; Menon, Malini; Campbell, James; Gulati, Aditi; Kumar, Rahul; Pettitt, Stephen J; Gurden, Mark D; Cardenosa, Marta Llorca; Chong, Irene; Gazinska, Patrycja; Wallberg, Fredrik; Sawyer, Elinor J; Martin, Lesley-Ann; Dowsett, Mitch; Linardopoulos, Spiros; Natrajan, Rachael; Ryan, Colm J; Derksen, Patrick W B; Jonkers, Jos; Tutt, Andrew N J; Ashworth, Alan; Lord, Christopher J
(2018) Cancer Discovery, volume 8, issue 4, pp. 498 - 515
(Article)
Abstract
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered CDH1 mutations, we identified synthetic lethality between E-cadherin deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale
... read more
genetic screens in molecularly diverse breast tumor cell lines established that the E-cadherin/ROS1 synthetic lethality was not only robust in the face of considerable molecular heterogeneity but was also elicited with clinical ROS1 inhibitors, including foretinib and crizotinib. ROS1 inhibitors induced mitotic abnormalities and multinucleation in E-cadherin–defective cells, phenotypes associated with a defect in cytokinesis and aberrant p120 catenin phosphorylation and localization. In vivo, ROS1 inhibitors produced profound antitumor effects in multiple models of E-cadherin–defective breast cancer. These data therefore provide the preclinical rationale for assessing ROS1 inhibitors, such as the licensed drug crizotinib, in appropriately stratified patients. SIGNIFICANCE: E-cadherin defects are common in breast cancer but are currently not targeted with a precision medicine approach. Our preclinical data indicate that licensed ROS1 inhibitors, including crizotinib, should be repurposed to target E-cadherin–defective breast cancers, thus providing the rationale for the assessment of these agents in molecularly stratified phase II clinical trials.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Journal Article
ISSN: 2159-8274
Publisher: American Association for Cancer Research Inc.
Note: Publisher Copyright: ©2018 American Association for Cancer Research.
(Peer reviewed)